Approved for use through 10/31/2008, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

EPT-001C2

Under the Papareock Reduction Act of 1995, no persons are required to respond to accelerate during these trues are personal to respond to accelerate during the acceleration of the control price of the computed to accelerate during the acceleration of the control price of the computed to accelerate during the acceleration of the computed to accelerate during the acceleration of the computed to th

Attorney Docket Number

2

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	A43*	US-4,970,171	11-13-1990	Messenger et al.		
	A44*	US-5,061,790	10-29-1991	Elting et al.		
	A45*	US-5,223,441	06-29-1993	Ullman et al.		
	A46*	US-6,955,915	10-18-2005	Fodor et al.	1	
	A47*	US-20040096901	05-20-2004	Aversa et al.		
	A48*	US-20050255491	11-17-2005	Lee et al.		
	A49*	US-20070224628	09-27-2007	Gordon et al.		
	A50*	US-20070224704	09-27-2007	Gordon et al.		

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>2</sup> -Number <sup>4</sup> -Kind Code <sup>2</sup> (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	т°		
	B12	EP-1320754	06-25-2003	Oxford Glycosciences (UK) Ltd.		П		
	B13	WO-03001879	01-09-2003	MDS Proteomics Inc.		П		
	B14	WO-0550224	06-02-2005	Epitome Biosystems, Inc.		П		
	B15	WO-07112012	10-04-2007	Epitome Biosystems, Inc.		П		
	B16	WO-07123708	11-01-2007	Epitome Biosystems, Inc.				
	B17	WO-9408597	04-28-1994	The Scripps Institute				
	B18	WO-9500851	01-05-1995	Boehringer Ingelheim Intl.		П		

Examiner	Date	
Signature	Considered	

EXAMINED Initial Indexense considered, whether or not classin is no conformance with IMPEP 000. Dawn line through classins if not in conformance and not considered include copy of this form with next communication to applicant. \*\*OTER\*\* OTER\*\* Displays (1) which are made with an eign assertant in the to the Cell No. see not supplied under 27 CFR\*\* 1.09(a)(2)(iii)) because that application was filled after June 30, 2002 of a whiteling in the IPP. \*\*Applicant's the Cell No. see not supplied under 27 CFR\*\* 1.09(a)(2)(iii)) because that application was filled after June 30, 2002 of a whiteling in the IPP. \*\*Applicant's the Cell No. see not supplied under 27 CFR\*\* 1.09(a)(2)(iii)) because the supplied of the IPP. \*\*Applicant IPP. \*\*

Sheet

PTOSS008 00-00 Approved for use through 100 12000. OBIG 00-00 Approved for use through 100 12000. OBIG 00-100 U.S. Paternt and Trademack Officer, U.S. DEPARTMENT OF COMMERCE Under the Pagerwork Reduction Act of 1995, no persons are required to respond to a collection of information unless a contains a valid ONG central number. Complete if Known Substitute for form 1449/PTO 10/773,032-Conf. #5991 Application Number INFORMATION DISCLOSURE Filing Date February 5, 2004 STATEMENT BY APPLICANT First Named Inventor Frank D. Lee Art Unit 1631 (Use as many sheets as necessary) Examiner Name J. Lin EPT-001C2 Sheet 2 of 2 Attorney Docket Number

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1				
	C57	Georges et al. (1990) "Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies," PNAS USA 87: 152-156			
	C58	Grubb et al. (2003) "Signal Pathway Profiling of Prostate Cancer using Reverse Phase Protein Arrays," Proteomics 3(11): 2142-2146.			
	C59	Gembitsky et al. (2004) "A prototype antibody microarray platform to monitor changes in protein tyrosine phosphorylation," Molec. Cellular Proteomics 3(11): 1102-1118.			
	C60	Dours-Zimmerman et al. (1994) "A Novel Glycosaminoglycan Attachment Domain Identified in Two Alternative Splice Variants of Human Versican," J. Biol. Chem. 269(52): 32992-98.			
	C61	Hongo et al. (1994) "Identification of Second Protein Encoded by Influenza C Virus RNA Segment 6," J. General Virology 75: 3503-3510.			
	C62	Mann et al. (2002) "Analysis of protein phosphorylation using mass spectrometry: deciphering the phosphoproteome," TRENDS in Biotechnol. 20(6): 261-68.			
	C63	Arenkov et al. (2000) "Protein Microchips: Use for Immunoassay and Enzymatic Reactions," Analyt. Biochem. 278: 123-131.			
	C64	Jemmerson (1987) "Antigenicity and Native Structure of Globular Proteins: Low Frequency of Peptide Reactive Antibodies," PNAS 84: 9180-84.			
	C65	Martegani et al. (1999) "Structural Variability of CD44v Molecules and Reliability of Immunodelection of CD44 Isoforms Using mAbs Specific for CD44 Variant Exon Products," American J. Pathology 154(1)			

Examiner	Date	
Signature	Considered	

\*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.